Trexquant Investment LP boosted its stake in Bruker Co. (NASDAQ:BRKR) by 32.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 29,939 shares of the medical research company’s stock after purchasing an additional 7,389 shares during the quarter. Trexquant Investment LP’s holdings in Bruker were worth $869,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Bruker during the second quarter worth about $101,000. Meeder Asset Management Inc. boosted its position in shares of Bruker by 501.4% during the first quarter. Meeder Asset Management Inc. now owns 4,697 shares of the medical research company’s stock worth $140,000 after buying an additional 3,916 shares during the period. TLP Group LLC acquired a new position in shares of Bruker during the first quarter worth about $190,000. Campbell & CO Investment Adviser LLC acquired a new position in Bruker during the first quarter valued at approximately $242,000. Finally, Strs Ohio acquired a new position in Bruker during the second quarter valued at approximately $327,000. Institutional investors and hedge funds own 65.61% of the company’s stock.

Bruker stock traded down $0.09 during mid-day trading on Friday, reaching $35.53. 420,582 shares of the company were exchanged, compared to its average volume of 459,066. Bruker Co. has a 12 month low of $28.13 and a 12 month high of $36.53. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.22 and a quick ratio of 1.27. The firm has a market cap of $5.51 billion, a PE ratio of 27.33, a price-to-earnings-growth ratio of 2.22 and a beta of 1.33.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, August 2nd. The medical research company reported $0.25 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.25. Bruker had a return on equity of 27.03% and a net margin of 4.99%. The company had revenue of $443.70 million for the quarter, compared to analyst estimates of $436.10 million. During the same quarter last year, the company posted $0.23 EPS. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. sell-side analysts expect that Bruker Co. will post 1.38 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 21st. Stockholders of record on Tuesday, September 4th will be paid a $0.04 dividend. The ex-dividend date is Friday, August 31st. This represents a $0.16 annualized dividend and a dividend yield of 0.45%. Bruker’s payout ratio is 13.22%.

Several brokerages recently commented on BRKR. BidaskClub cut Bruker from a “buy” rating to a “hold” rating in a research report on Wednesday, June 20th. Morgan Stanley cut their price objective on Bruker from $31.00 to $29.00 and set an “equal weight” rating for the company in a research report on Friday, July 13th. Zacks Investment Research cut Bruker from a “buy” rating to a “hold” rating in a research report on Friday, June 8th. Finally, ValuEngine cut Bruker from a “hold” rating to a “sell” rating in a research report on Wednesday, July 11th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the stock. Bruker currently has an average rating of “Hold” and an average target price of $33.20.

Bruker Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Further Reading: What do I need to know about analyst ratings?

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.